ValuEngine downgraded shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from a buy rating to a hold rating in a research note issued to investors on Friday morning.

Several other equities analysts also recently weighed in on TEVA. Maxim Group set a $35.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the stock a hold rating in a research note on Thursday, May 11th. Deutsche Bank AG decreased their price target on shares of Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a buy rating on the stock in a research note on Friday, May 12th. Royal Bank Of Canada reissued an outperform rating and issued a $38.00 price target (down from $42.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Monday, May 15th. Credit Suisse Group reissued a buy rating and issued a $39.00 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, May 17th. Finally, Vetr raised shares of Teva Pharmaceutical Industries Limited from a buy rating to a strong-buy rating and set a $34.25 price target on the stock in a research note on Wednesday, May 17th. Four investment analysts have rated the stock with a sell rating, twenty have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $34.50.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 15.90 on Friday. The stock’s market capitalization is $16.15 billion. Teva Pharmaceutical Industries Limited has a 12 month low of $15.32 and a 12 month high of $52.66. The stock’s 50 day moving average is $23.15 and its 200 day moving average is $29.75.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. The business had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business’s quarterly revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.25 earnings per share. Analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Stock Rating Lowered by ValuEngine” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/05/teva-pharmaceutical-industries-limited-teva-stock-rating-lowered-by-valuengine.html.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be issued a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.14%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is currently -15.36%.

A number of hedge funds and other institutional investors have recently bought and sold shares of TEVA. San Francisco Sentry Investment Group CA acquired a new position in Teva Pharmaceutical Industries Limited during the 2nd quarter worth approximately $106,000. Bronfman E.L. Rothschild L.P. grew its holdings in Teva Pharmaceutical Industries Limited by 7.8% during the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after acquiring an additional 261 shares in the last quarter. Kistler Tiffany Companies LLC grew its holdings in Teva Pharmaceutical Industries Limited by 74.7% during the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after acquiring an additional 1,571 shares in the last quarter. FNY Managed Accounts LLC acquired a new position in Teva Pharmaceutical Industries Limited during the 1st quarter worth approximately $123,000. Finally, Sterling Investment Advisors Ltd. grew its holdings in Teva Pharmaceutical Industries Limited by 2.6% during the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after acquiring an additional 100 shares in the last quarter. Institutional investors own 56.87% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.